Page 53 - NobleCon20-Book-Project

Connect Biopharma Holdings Limited

SELECTED FINANCIAL ITEMS CNTB

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue NA NA 12.06 12.06 24.12
Gross Profit NA NA 12.06 12.06 24.12
Gross Margin NM NM 100% 100% 100%
EBIT (16.59) (16.13) 2.97 2.97 (26.77)
EBIT Margin NM NM 25% 25% -111%
Net Income to Common Shareholders (15.23) (14.81) 3.82 3.82 (22.38)
Net Margin NM NM 32% 32% -93%

Balance Sheet Key Items
Total Assets 125.89 125.89 120.57 120.57 120.57
Cash & Short Term Investments 106.01 106.01 110.17 110.17 110.17
% of Assets 84% 84% 91% 91% 91%
Current Assets -Total 120.97 120.97 115.90 115.90 115.90
% of Assets 96% 96% 96% 96% 96%
Total Liabilities 24.85 24.85 10.09 10.09 10.09
% of Assets 20% 20% 8% 8% 8%
Current Liabilities - Total 24.26 24.26 9.62 9.62 9.62
% of Assets 19% 19% 8% 8% 8%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 101.04 101.04 110.48 110.48 110.48
% of Assets 80% 80% 92% 92% 92%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (9.20) (8.77) (3.99) (3.99) (25.95)
Net Cash Flow - Investing 21.31 20.84 6.14 6.14 54.43
Net Cash Flow - Financing (0.06) (0.06) (0.02) (0.02) (0.17)

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference